Intravenous Immunoglobulin for Unexplained Recurrent Pregnancy Loss: Current Evidence, Guideline Positions, and Considerations for Home Infusion Nursing
DOMO Health Clinical Team, Durham, North Carolina
Abstract
Background. Recurrent pregnancy loss (RPL) affects a meaningful share of people trying to conceive, and many cases remain unexplained after evaluation. Intravenous immunoglobulin (IVIG) has been studied for unexplained RPL for more than three decades. It is not approved by the U.S. Food and Drug Administration (FDA) for this indication.
Objective. To summarize the randomized evidence and current guideline positions on IVIG for unexplained RPL, and to describe the safety, access, and nursing considerations relevant when IVIG is prescribed and administered in the home.
Findings. A 2014 Cochrane review found no significant effect of IVIG on live birth across 8 trials (303 women). A 2015 randomized trial in secondary RPL found no significant difference. A 2022 double-blind randomized trial of high-dose IVIG started at 4 to 6 weeks of gestation in women with four or more unexplained primary losses reported higher ongoing pregnancy and live birth rates than placebo. The European Society of Human Reproduction and Embryology (ESHRE) now issues a conditional recommendation that this regimen may improve live birth in that population, while calling for further trials. The American Society for Reproductive Medicine (ASRM) 2026 committee opinion advises against routine use of treatments lacking strong evidence of benefit.
Conclusion. The evidence remains limited and inconsistent. Decisions belong to patients and their reproductive specialists. When IVIG is prescribed, home administration requires the same standards applied to any IVIG infusion, with added attention to the thrombotic risk of pregnancy.
Introduction
ASRM defines RPL as the spontaneous loss of two or more pregnancies, excluding molar and ectopic pregnancies; the losses need not be consecutive [1]. ESHRE uses the same threshold of two or more losses [2]. Evaluation commonly includes chromosomal analysis of pregnancy tissue where available, targeted testing guided by history, and screening for conditions such as thyroid disease and diabetes [1]. When no cause is identified, RPL is classified as unexplained.
The prognosis for many patients is favorable. ASRM notes that 50 to 80 percent of patients with RPL go on to have a successful pregnancy, even without medical intervention [8]. That baseline matters when interpreting any treatment study, because a high spontaneous success rate makes benefit difficult to detect and easy to overstate.
Home infusion providers are increasingly receiving inquiries from patients about IVIG for RPL. This review summarizes the evidence and guideline landscape so that nurses, pharmacies, and referral partners can respond accurately, and it outlines the practice considerations for home administration when a prescriber orders it.
Rationale for immunomodulation
Successful pregnancy requires maternal immune tolerance of a semi-allogeneic fetus. The hypothesis behind immunotherapy for unexplained RPL is that some losses reflect dysregulation of that tolerance. IVIG, a pooled plasma-derived product with broad immunomodulatory effects, has been studied as one means of restoring it. The biological rationale is plausible, but a plausible mechanism does not establish clinical benefit.
Randomized evidence
Study: Wong et al., Cochrane review, 2014 [3] | Population: 8 IVIG trials, 303 women with recurrent miscarriage | Intervention: IVIG vs placebo | Outcome: No significant effect on live birth (Peto OR 0.98, 95% CI 0.61 to 1.58)
Study: Christiansen et al., BJOG, 2015 [4] | Population: 82 women, unexplained secondary RPL, 4 or more losses | Intervention: IVIG vs placebo | Outcome: Live birth 54.8% vs 50.0% (RR 1.11, 95% CI 0.70 to 1.74), not significant
Study: Yamada et al., EClinicalMedicine, 2022 [5] | Population: 102 randomized (99 analyzed), unexplained primary RPL, 4 or more losses, at least one euploid loss | Intervention: 400 mg/kg/day for 5 days, started at 4 to 6 weeks | Outcome: Ongoing pregnancy at 22 weeks 62.0% vs 34.7% (OR 3.07, 95% CI 1.35 to 6.97); live birth 58.0% vs 34.7% (OR 2.60, 95% CI 1.15 to 5.86)
The trial by Yamada and colleagues is the strongest positive result to date [5]. Its effect was concentrated in women who began treatment at 4 to 5 weeks and was not evident when treatment began at 6 weeks. Four newborns in the IVIG group had congenital anomalies compared with none in the placebo group; the difference was not statistically significant (p = 0.28), but the sample was small. The trial was funded by a blood products organization, enrolled a narrowly defined population, and has not yet been replicated.
The negative findings of the Cochrane review and the Christiansen trial involved different populations, regimens, and timing, which may explain some of the inconsistency [3,4]. Observational studies continue to appear; for example, a 2025 single-center retrospective cohort reported similar live birth rates in IVIG-treated patients with abnormal cellular immune markers and untreated patients with normal markers [6]. Retrospective designs of this kind cannot establish efficacy.
Guideline positions
Organization: ESHRE, 2022 update [2] | Position: Conditional: repeated high-dose IVIG very early in pregnancy may improve live birth in women with 4 or more unexplained losses; based on one high-quality trial; more trials needed
Organization: ASRM, 2026 committee opinion [1,8] | Position: Recommends targeted evaluation and emotional support, and avoiding routine use of tests and treatments that lack strong evidence of benefit
Safety considerations
All immune globulin products carry an FDA boxed warning for thrombosis, and IVIG products also carry a boxed warning for renal dysfunction and acute renal failure [9]. Risk factors listed in product labeling include hypercoagulable states and estrogen use. Pregnancy is itself a hypercoagulable state, so thrombotic risk warrants specific assessment before and during any course of IVIG in pregnancy. Label mitigation applies: the minimum dose and infusion rate practicable and adequate hydration before administration [9]. High-dose, multi-day regimens of the kind studied for RPL increase cumulative exposure, which places greater weight on hydration status, rate titration, and monitoring at every visit.
Other adverse effects are those seen with IVIG generally, including headache, flushing, chills, myalgia, nausea, aseptic meningitis, hemolysis, and hypersensitivity reactions.
Coverage and access
Coverage for IVIG in RPL is limited. At least some commercial medical policies classify it as experimental or investigational [7]. Patients should receive a benefits investigation and a clear explanation of potential out-of-pocket cost before treatment begins. Pharmacies and nursing providers should not represent that coverage is likely.
Implications for home infusion nursing
When IVIG is prescribed for RPL, the home infusion nurse does not determine appropriateness; that responsibility rests with the prescriber. The nurse's role is safe execution and accurate reporting:
Verify the order, product, lot, expiration, and weight-based dose, including current pregnancy weight.
Assess hydration and thrombotic risk factors before each infusion and report concerns to the prescriber.
Titrate the rate from a low starting rate according to product labeling and the order, with vital signs at baseline, at each rate change, and at completion.
Maintain anaphylaxis readiness at every visit.
Recognize that early pregnancy symptoms such as nausea, fatigue, and headache can overlap with infusion reactions, and document carefully to distinguish them.
Coordinate with the prescriber and obstetric team on symptoms that require escalation, including bleeding, cramping, or signs of thrombosis.
Document to the standards of the Infusion Nurses Society and the receiving pharmacy, including lot traceability [10].
Communication with patients should be accurate and restrained. Nurses should not characterize the likelihood of benefit, and should refer questions about efficacy to the prescriber.
Discussion
The evidence for IVIG in unexplained RPL is limited, inconsistent across populations, and dependent on a single positive randomized trial in a narrowly defined group. Guideline bodies interpret that evidence differently. Against a background in which most patients with RPL eventually achieve a successful pregnancy without treatment, claims of benefit for any intervention require strong evidence. Families facing RPL are often making decisions under significant emotional strain, which places an ethical obligation on every member of the care team to communicate the uncertainty plainly.
Conclusion
IVIG is not FDA approved for RPL, and its role remains unsettled. Decisions about its use belong to patients and their reproductive specialists, informed by the specific population studied and an honest discussion of risk, cost, and uncertainty. When IVIG is prescribed, home infusion providers contribute by delivering it to the same rigorous standard as any IVIG therapy and by keeping the prescriber informed.
Disclosure. This article was prepared by the clinical team of DOMO Health, a specialty home infusion nursing provider that may administer IVIG when prescribed. DOMO Health does not prescribe medications or make treatment recommendations. This article is educational and is not medical advice.
References
Practice Committee of the American Society for Reproductive Medicine. Recurrent pregnancy loss: a committee opinion. Fertil Steril. 2026.
Bender Atik R, et al. ESHRE guideline: recurrent pregnancy loss: an update in 2022. Hum Reprod Open. 2023;2023(1):hoad002.
Wong LF, Porter TF, Scott JR. Immunotherapy for recurrent miscarriage. Cochrane Database Syst Rev. 2014;(10):CD000112.
Christiansen OB, Larsen EC, Egerup P, Lunoee L, Egestad L, Nielsen HS. Intravenous immunoglobulin treatment for secondary recurrent miscarriage: a randomised, double-blind, placebo-controlled trial. BJOG. 2015;122(4):500-8.
Yamada H, Deguchi M, Saito S, et al. Intravenous immunoglobulin treatment in women with four or more recurrent pregnancy losses: a double-blind, randomised, placebo-controlled trial. EClinicalMedicine. 2022;50:101527.
Han JW, Park JS, Kim JS, Lee SK. Efficacy of intravenous immunoglobulin in recurrent pregnancy loss: a retrospective analysis of patients with abnormal cellular immunity. Front Endocrinol. 2025;16:1546602.
Blue Cross Blue Shield of Michigan. Intravenous Immune Globulin (IVIG) for Recurrent Early Pregnancy Loss. Medical policy.
American Society for Reproductive Medicine. ASRM releases first updated guidance on recurrent pregnancy loss in over a decade. Press release, June 1, 2026.
FDA prescribing information for immune globulin intravenous (human) products, boxed warnings for thrombosis and renal dysfunction (for example, Gamunex-C, Octagam 10%, Gammaplex).
Infusion Nurses Society. Infusion Therapy Standards of Practice, 9th edition. J Infus Nurs. 2024.
Comments